Drugs / SOF/VEL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02201953 | Jul 2014 → Sep 2015 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-01-20 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOF/VEL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02201953 ↗ |
| Action | Inhibit | “the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir” PMID 26575258 ↗ Nov 2015 |
| Route | Oral | “400/100 mg FDC tablet administered orally once daily” NCT02201953 ↗ |